Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function

Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF)

(2020) Robert Webb et al.   TOXICON

Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins

(2020) Kwok-ho Lam et al.   Cell Reports

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice

(2019) Godakova et al.   Toxins

Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination against Botulinum C and D Neurotoxins

(2019) Doris M. Snow et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Evolution of Polystyrene as a Cell Culture Material

(2018) Max J. Lerman et al.   TISSUE ENGINEERING PART B-REVIEWS

Nanobodies as novel therapeutic agents in envenomation

(2018) Ehsan Alirahimi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Botulinum and Tetanus Neurotoxins

(2018) Min Dong et al.   Annual Review of Biochemistry

Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin

(2017) Nai-Jia Huang et al.   Nature Communications

Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism

(2017) Robert P. Webb et al.   Toxins

Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery

(2017) Edwin J. Vazquez-Cintron et al.   Scientific Reports

A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection

(2016) Diane J. Schmidt et al.   Clinical and Vaccine Immunology

A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection

(2016) Catherine E. Vrentas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Solubility of the catalytic domains of Botulinum neurotoxin serotype E subtypes

(2016) Sheng Chen et al.   PROTEIN EXPRESSION AND PURIFICATION

A Heterodimer of a VHH (Variable Domains of Camelid Heavy Chain-only) Antibody That Inhibits Anthrax Toxin Cell Binding Linked to a VHH Antibody That Blocks Oligomer Formation Is Highly Protective in an Anthrax Spore Challenge Model

(2015) Mahtab Moayeri et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Botulinum and Tetanus Neurotoxin-Induced Blockade of Synaptic Transmission in Networked Cultures of Human and Rodent Neurons

(2015) Phillip H. Beske et al.   TOXICOLOGICAL SCIENCES

Heat-Labile Enterotoxin IIa, a Platform To Deliver Heterologous Proteins into Neurons

(2015) Chen Chen et al.   mBio

Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A

(2014) S. U. Nayak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential role of molten globule and protein folding in distinguishing unique features of botulinum neurotoxin

(2014) Raj Kumar et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Adenovirus Vector Expressing Stx1/Stx2-Neutralizing Agent Protects Piglets Infected with Escherichia coli O157:H7 against Fatal Systemic Intoxication

(2014) Abhineet S. Sheoran et al.   INFECTION AND IMMUNITY

A Novel Multivalent, Single-Domain Antibody Targeting TcdA and TcdB Prevents Fulminant Clostridium difficile Infection in Mice

(2014) Zhiyong Yang et al.   JOURNAL OF INFECTIOUS DISEASES

A general protocol for the generation of Nanobodies for structural biology

(2014) Els Pardon et al.   Nature Protocols

Prolonged Prophylactic Protection from Botulism with a Single Adenovirus Treatment Promoting Serum Expression of a VHH-Based Antitoxin Protein

(2014) Jean Mukherjee et al.   PLoS One

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

A Single VHH-Based Toxin-Neutralizing Agent and an Effector Antibody Protect Mice against Challenge with Shiga Toxins 1 and 2

(2013) Jacqueline M. Tremblay et al.   INFECTION AND IMMUNITY

Stepwise Engineering of Heterodimeric Single Domain Camelid VHH Antibodies That Passively Protect Mice from Ricin Toxin

(2013) David J. Vance et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In Vivo Neutralization of Botulinum Neurotoxins Serotype E with Heavy-chain Camelid Antibodies (VHH)

(2013) Hamid Bakherad et al.   MOLECULAR BIOTECHNOLOGY

Novel Application of Stem Cell-Derived Neurons to Evaluate the Time- and Dose-Dependent Progression of Excitotoxic Injury

(2013) Ian M. Gut et al.   PLoS One

A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model

(2012) Jean Mukherjee et al.   PLoS One

Botulinum Neurotoxins and Botulism: A Novel Therapeutic Approach

(2011) Jeeraphong Thanongsaksrikul et al.   Toxins

A Single-Domain Llama Antibody Potently Inhibits the Enzymatic Activity of Botulinum Neurotoxin by Binding to the Non-Catalytic α-Exosite Binding Region

(2010) Jianbo Dong et al.   JOURNAL OF MOLECULAR BIOLOGY

Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases

(2010) Jacqueline M. Tremblay et al.   TOXICON

Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease

(2010) Lisa M. Eubanks et al.   ACS Medicinal Chemistry Letters

Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents

(2009) J. Sepulveda et al.   INFECTION AND IMMUNITY

Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3

(2009) Robert P. Webb et al.   VACCINE